IL-17, IL-23 Therapies Lead Psoriasis Care - Top-Institutions - MDSpire

IL-17, IL-23 Therapies Lead Psoriasis Care

Network meta-analysis suggests higher PASI 90 response rates with biologics vs oral systemic therapies

  • By

  • Andrea Surnit

  • April 12, 2026

  • 3 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    University of California, Los Angeles (UCLA) Health
    University of California, Los Angeles (UCLA) Health

    Los Angeles, CA

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Research

  • #2

    University of Pennsylvania Perelman School of Medicine
    University of Pennsylvania Perelman School of Medicine

    Philadelphia, PA

    Key Differentiators

    • Dermatology
    • Immunology
    • Translational Medicine

  • #3

    Massachusetts General Hospital (MGH) / Harvard Medical School
    Massachusetts General Hospital (MGH) / Harvard Medical School

    Boston, MA

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Trials

  • #4

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, CA

    Key Differentiators

    • Dermatology
    • Immunology
    • Clinical Research

  • #5

    Cleveland Clinic
    Cleveland Clinic

    Cleveland, OH

    Key Differentiators

    • Dermatology
    • Clinical Trials
    • Immunology

Original Source(s)

IL-17, IL-23 Therapies Lead Psoriasis Care

  • by Andrea Surnit

  • April 12, 2026

Related Content

FDA Clears Golimumab Biosimilars

New biosimilars enter the market with pharmacy-level substitution eligibility for rheumatology and gastroenterology indications.

AD Not Linked to Early CV Risk Markers

Repeated assessments from childhood to early adulthood did not identify consistent cardiometabolic risk patterns by disease activity or severity.

Biologics Commonly Used in Cutaneous Crohn's Disease

Retrospective multicenter cohort highlights genital-predominant presentation patterns and frequent combination therapy use in cutaneous Crohn's disease.